Laidlaw cut shares of Repros Therapeutics Inc. (NASDAQ:RPRX) from a buy rating to a neutral rating in a research note published on Friday.

Shares of Repros Therapeutics (NASDAQ:RPRX) traded down 6.3038% during trading on Friday, reaching $0.3701. 605,985 shares of the company’s stock were exchanged. The company’s 50-day moving average is $0.44 and its 200 day moving average is $0.94. The stock’s market capitalization is $9.89 million. Repros Therapeutics has a 52 week low of $0.30 and a 52 week high of $2.48.

Repros Therapeutics (NASDAQ:RPRX) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.08. The firm had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative net margin of 49,564.86% and a negative return on equity of 276.50%. On average, analysts forecast that Repros Therapeutics will post ($1.07) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Repros Therapeutics Inc. (RPRX) Lowered to “Neutral” at Laidlaw” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at

A hedge fund recently raised its stake in Repros Therapeutics stock. Renaissance Technologies LLC raised its stake in Repros Therapeutics Inc. (NASDAQ:RPRX) by 7.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 716,413 shares of the biotechnology company’s stock after buying an additional 49,300 shares during the period. Renaissance Technologies LLC owned about 2.82% of Repros Therapeutics worth $946,000 as of its most recent SEC filing. 21.71% of the stock is owned by institutional investors and hedge funds.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with's FREE daily email newsletter.